List of Tables
Table 1. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Oral Drugs for Benign Prostatic Hyperplasia Market Competitive Situation by Manufacturers in 2024
Table 4. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Oral Drugs for Benign Prostatic Hyperplasia Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Oral Drugs for Benign Prostatic Hyperplasia, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Product Type & Application
Table 12. Global Key Manufacturers of Oral Drugs for Benign Prostatic Hyperplasia, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oral Drugs for Benign Prostatic Hyperplasia by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Drugs for Benign Prostatic Hyperplasia as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2020-2025) & (K Units)
Table 18. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2020-2025)
Table 19. Global Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2026-2031) & (K Units)
Table 20. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2026-2031)
Table 21. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2020-2025)
Table 23. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2026-2031)
Table 25. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2020-2025) & (K Units)
Table 27. North America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2026-2031) & (K Units)
Table 28. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2020-2025) & (K Units)
Table 32. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2026-2031) & (K Units)
Table 33. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Type (2020-2025)
Table 51. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Type (2026-2031)
Table 52. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2020-2025)
Table 53. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Type (2026-2031)
Table 54. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2020-2025)
Table 57. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Type (2026-2031)
Table 58. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Type (2020-2025)
Table 59. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Type (2026-2031)
Table 60. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Application (2020-2025)
Table 61. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units) by Application (2026-2031)
Table 62. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2020-2025)
Table 63. Global Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Application (2026-2031)
Table 64. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2020-2025)
Table 67. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Application (2026-2031)
Table 68. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Application (2020-2025)
Table 69. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Application (2026-2031)
Table 70. Eli Lilly Company Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Eli Lilly Oral Drugs for Benign Prostatic Hyperplasia Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. GlaxoSmithKline Company Information
Table 76. GlaxoSmithKline Description and Business Overview
Table 77. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. GlaxoSmithKline Oral Drugs for Benign Prostatic Hyperplasia Product
Table 79. GlaxoSmithKline Recent Developments/Updates
Table 80. Astellas Pharma Company Information
Table 81. Astellas Pharma Description and Business Overview
Table 82. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Astellas Pharma Oral Drugs for Benign Prostatic Hyperplasia Product
Table 84. Astellas Pharma Recent Developments/Updates
Table 85. Sanofi Company Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Sanofi Oral Drugs for Benign Prostatic Hyperplasia Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Pfizer Company Information
Table 91. Pfizer Description and Business Overview
Table 92. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Pfizer Oral Drugs for Benign Prostatic Hyperplasia Product
Table 94. Pfizer Recent Developments/Updates
Table 95. Abbott Company Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Abbott Oral Drugs for Benign Prostatic Hyperplasia Product
Table 99. Abbott Recent Developments/Updates
Table 100. Allergan Company Information
Table 101. Allergan Description and Business Overview
Table 102. Allergan Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Allergan Oral Drugs for Benign Prostatic Hyperplasia Product
Table 104. Allergan Recent Developments/Updates
Table 105. TEVA Company Information
Table 106. TEVA Description and Business Overview
Table 107. TEVA Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. TEVA Oral Drugs for Benign Prostatic Hyperplasia Product
Table 109. TEVA Recent Developments/Updates
Table 110. Viatris Company Information
Table 111. Viatris Description and Business Overview
Table 112. Viatris Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Viatris Oral Drugs for Benign Prostatic Hyperplasia Product
Table 114. Viatris Recent Developments/Updates
Table 115. Novartis Company Information
Table 116. Novartis Description and Business Overview
Table 117. Novartis Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Novartis Oral Drugs for Benign Prostatic Hyperplasia Product
Table 119. Novartis Recent Developments/Updates
Table 120. Merck Company Information
Table 121. Merck Description and Business Overview
Table 122. Merck Oral Drugs for Benign Prostatic Hyperplasia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. Merck Oral Drugs for Benign Prostatic Hyperplasia Product
Table 124. Merck Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Oral Drugs for Benign Prostatic Hyperplasia Distributors List
Table 128. Oral Drugs for Benign Prostatic Hyperplasia Customers List
Table 129. Oral Drugs for Benign Prostatic Hyperplasia Market Trends
Table 130. Oral Drugs for Benign Prostatic Hyperplasia Market Drivers
Table 131. Oral Drugs for Benign Prostatic Hyperplasia Market Challenges
Table 132. Oral Drugs for Benign Prostatic Hyperplasia Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Oral Drugs for Benign Prostatic Hyperplasia
Figure 2. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Oral Drugs for Benign Prostatic Hyperplasia Market Share by Type: 2024 & 2031
Figure 4. Alpha Blockers Product Picture
Figure 5. 5-alpha Reductase Inhibitors Product Picture
Figure 6. Others Product Picture
Figure 7. Global Oral Drugs for Benign Prostatic Hyperplasia Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Oral Drugs for Benign Prostatic Hyperplasia Market Share by Application: 2024 & 2031
Figure 9. Hospitals
Figure 10. Drugstores
Figure 11. Others
Figure 12. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size (2020-2031) & (US$ Million)
Figure 14. Global Oral Drugs for Benign Prostatic Hyperplasia Sales (2020-2031) & (K Units)
Figure 15. Global Oral Drugs for Benign Prostatic Hyperplasia Average Price (US$/Unit) & (2020-2031)
Figure 16. Oral Drugs for Benign Prostatic Hyperplasia Report Years Considered
Figure 17. Oral Drugs for Benign Prostatic Hyperplasia Sales Share by Manufacturers in 2024
Figure 18. Global Oral Drugs for Benign Prostatic Hyperplasia Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Oral Drugs for Benign Prostatic Hyperplasia Players: Market Share by Revenue in Oral Drugs for Benign Prostatic Hyperplasia in 2024
Figure 20. Oral Drugs for Benign Prostatic Hyperplasia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Oral Drugs for Benign Prostatic Hyperplasia Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2020-2031)
Figure 23. North America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2020-2031)
Figure 24. United States Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2020-2031)
Figure 27. Europe Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2020-2031)
Figure 28. Germany Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Region (2020-2031)
Figure 35. China Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Indonesia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Thailand Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 43. Malaysia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 44. Latin America Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2020-2031)
Figure 45. Latin America Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2020-2031)
Figure 46. Mexico Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Brazil Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 48. Argentina Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 49. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Sales Market Share by Country (2020-2031)
Figure 50. Middle East and Africa Oral Drugs for Benign Prostatic Hyperplasia Revenue Market Share by Country (2020-2031)
Figure 51. Turkey Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Saudi Arabia Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 53. UAE Oral Drugs for Benign Prostatic Hyperplasia Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 54. Global Sales Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Type (2020-2031)
Figure 55. Global Revenue Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Type (2020-2031)
Figure 56. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Type (2020-2031)
Figure 57. Global Sales Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Application (2020-2031)
Figure 58. Global Revenue Market Share of Oral Drugs for Benign Prostatic Hyperplasia by Application (2020-2031)
Figure 59. Global Oral Drugs for Benign Prostatic Hyperplasia Price (US$/Unit) by Application (2020-2031)
Figure 60. Oral Drugs for Benign Prostatic Hyperplasia Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
